Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Can-Fite Biopharma Ltd ADR
(NY:
CANF
)
2.370
+0.160 (+7.24%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
48,263
Open
2.240
Bid (Size)
2.300 (1)
Ask (Size)
2.370 (10)
Prev. Close
2.210
Today's Range
2.240 - 2.470
52wk Range
1.810 - 4.690
Shares Outstanding
515,746,293
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
August 09, 2024
Via
ACCESSWIRE
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
June 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Performance
YTD
+14.49%
+14.49%
1 Month
-32.67%
-32.67%
3 Month
-2.07%
-2.07%
6 Month
+12.86%
+12.86%
1 Year
-13.82%
-13.82%
More News
Read More
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
June 24, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can Fite Biofarma: Q4 Earnings Insights
March 28, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
June 14, 2024
Via
Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
June 10, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
June 05, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
May 29, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
May 27, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
May 23, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
May 13, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
May 10, 2024
Via
ACCESSWIRE
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
May 09, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
May 06, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 25, 2024
Via
Benzinga
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
April 25, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
April 15, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
April 03, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023
March 28, 2024
Via
InvestorPlace
Can-Fite Reports 2023 Financial Results and Clinical Update
March 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
March 11, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
February 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
January 30, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
January 29, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.